GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Debt-to-Revenue

Knight Therapeutics (TSX:GUD) Debt-to-Revenue : 0.23 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Knight Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$19.6 Mil. Knight Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$49.5 Mil. Knight Therapeutics's annualized Revenue for the quarter that ended in Dec. 2023 was C$296.8 Mil. Knight Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.23.


Knight Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Knight Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Debt-to-Revenue Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.31 0.28 0.17 0.27 0.21

Knight Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.25 0.22 0.25 0.23

Competitive Comparison of Knight Therapeutics's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Debt-to-Revenue falls into.



Knight Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Knight Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(19.578 + 49.513) / 328.199
=0.21

Knight Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(19.578 + 49.513) / 296.788
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Knight Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (TSX:GUD) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Executives
Sime Armoyan 10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines